Fosun Pharma (China)

Recent papers from Fosun Pharma (China)

1. Reactive Compatibilization of Zizania latifolia Leaf Powder‐Reinforced Biodegradable Polyester Composites With a Grafted Compatibilizer and an Epoxy Chain ExtenderPolymer Composites · 2026
2. Dual trigger with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin versus gonadotropin-releasing hormone agonist alone in predicted high responders using antagonist protocol: a systematic review and meta-analysisJournal of Ovarian Research · 2026
3. On-DNA Radical Iodosulfonylation of Alkynes: Access to Bifunctional Covalent Warheads and Modular ScaffoldsOrganic Letters · 2026
4. A chemically optimized, GalNAc-conjugated siRNA targeting HSD17B13 demonstrates efficacy in a human 3D organoid model of MASH, showcasing an alternative to animal testingPLoS ONE · 2026
5. Discovery andCharacterization of RP04340 : A Highly Potent and OrallyActive Pan-KRAS PROTAC DegraderJournal of Medicinal Chemistry · 2026
6. Randomized Clinical Trials of Deutaleglitazar in Healthy Participants and in Patients with Diabetic Kidney DiseaseKidney International Reports · 2026
7. Luvometinib in recurrent/refractory pediatric Langerhans cell histiocytosis: a single-arm, multi-center, phase 2 trialBlood Cancer Journal · 2026
8. Pharmacokinetics, safety, and pharmacodynamics of intravenous methoxyethyl etomidate hydrochloride (ET-26-HCl) in Chinese participants with hepatic impairmentFrontiers in Pharmacology · 2026
9. Huoling Shengji granule in amyotrophic lateral sclerosis: A multicenter, randomized, double-blind, riluzole-controlled trialNeurotherapeutics · 2026
10. Correction: Novel derivatives of brincidofovir and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine inhibit orthopoxviruses and human adenoviruses more potently than brincidofovirSignal Transduction and Targeted Therapy · 2026
11. Reducing or omitting dexamethasone with NEPA and olanzapine for prevention of chemotherapy-induced nausea and vomiting in highly emetogenic chemotherapy: a randomized non-inferiority phase III trialJournal of Clinical Oncology · 2026
12. Fovinaciclib for First-Line Therapy of Advanced Breast CancerJAMA Oncology · 2026
13. Luvometinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: A randomized, double-blind, placebo-controlled, phase 3 trial.Journal of Clinical Oncology · 2026
14. Safety and efficacy of CS2009, a first-in-class PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced non-small cell lung cancer: Results from a phase 1/2 study.Journal of Clinical Oncology · 2026
15. Fovinaciclib versus placebo combined with fulvestrant for advanced breast cancer after endocrine therapy: A randomized, double-blind phase 3 trial.Journal of Clinical Oncology · 2026
16. DZD6008, a fourth-generation EGFR TKI, in pretreated NSCLC patients with EGFR C797X mutations: Results from phase 1/2 studies.Journal of Clinical Oncology · 2026
17. CS2009, a novel PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced solid tumors: Updated results from an open-label, multicenter, phase 1 first-in-human study.Journal of Clinical Oncology · 2026
18. Identification of candidate genes and ceRNA networks of HPG axis in regulating sexual precocity of roosters by whole transcriptomic sequencingBMC Genomics · 2026
19. A phase 2 study of the MEK1/2 inhibitor luvometinib in patients with extracranial arteriovenous malformationsClinical Cancer Research · 2026
20. 3D Printing Mesoporous Silica Nanoparticles/ PCL With Controlled Drug Release for Pet DewormingPolymers for Advanced Technologies · 2026